title: Surgery for cure followed by combined modality treatment for small cell bronchial carcinoma. ISC Lung Cancer Study Group.
abstract: For patients with small cell lung cancer (SCLC) at early stages (TNM I, II) surgery for cure is used to eliminate the primary tumour and its regional lymph-nodes followed by intermittent chemotherapy and radiotherapy within the first six postoperative months. After the pathohistological examination of the operation-specimen a two-arm-randomization is performed: standard chemotherapy compared with sequential chemotherapy using three different drug-combinations. Thereafter tumour-free patients only receive prophylactic cranial irradiation. In preliminary evaluations of March 1988, of 121 patients from 20 cooperating departments it was found that the projected life-table survival rate, three years postoperatively, of 47 patients with SCLC at stages pT1-3 N0 M0 was 65%, of 46 patients at stages pT1-3 N1 M0, 56% and of 28 patients at stages pT1-3 N2 M0, 34%. The indication for surgery were emphasized for pTNM-stages I+II. For N2-lesions surgery would not be recommended in general, but the survival rate seemed to indicate that this treatment was not detrimental, but rather more favourable compared with chemotherapy or radiotherapy only. The continuation and enlargement of these studies seem not only justified but emphatically indicated. Multicentre cooperation has to be organized to collect within a reasonable period of time a sufficient number of patients to enable subdivisions to be made according to various prognostic factors.
authors.affiliation: International Society of Chemotherapy Study Centre, Institute for Epidemiology of Neoplasms, University of Vienna, Austria.
authors.forename: K
authors.initials: K
authors.lastname: Karrer
authors.forename: H
authors.initials: H
authors.lastname: Denck
authors.forename: H
authors.initials: H
authors.lastname: Karnicka-Mlodkowska
authors.forename: P
authors.initials: P
authors.lastname: Drings
authors.forename: J
authors.initials: J
authors.lastname: Erzen
authors.forename: D
authors.initials: D
authors.lastname: Dell'Amore
authors.forename: M
authors.initials: M
authors.lastname: Thermann
authors.forename: G M
authors.initials: GM
authors.lastname: Salzer
authors.forename: Y
authors.initials: Y
authors.lastname: Sun
authors.forename: M L
authors.initials: ML
authors.lastname: Liao
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002283:Carcinoma, Bronchogenic / Q000401:mortality / Q000601:surgery / Q000628:therapy*; D018288:Carcinoma, Small Cell / Q000401:mortality / Q000601:surgery / Q000628:therapy*; D003131:Combined Modality Therapy; D006801:Humans; D008175:Lung Neoplasms / Q000401:mortality / Q000601:surgery / Q000628:therapy*; D015337:Multicenter Studies as Topic
chemical_list: D000970:Antineoplastic Agents